S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon

Replimune Group (REPL) Competitors

$6.45
-0.52 (-7.46%)
(As of 04/19/2024 ET)

REPL vs. VYGR, TRML, CCCC, OCGN, LXEO, EDIT, ADPT, ITOS, TSHA, and ALEC

Should you be buying Replimune Group stock or one of its competitors? The main competitors of Replimune Group include Voyager Therapeutics (VYGR), Tourmaline Bio (TRML), C4 Therapeutics (CCCC), Ocugen (OCGN), Lexeo Therapeutics (LXEO), Editas Medicine (EDIT), Adaptive Biotechnologies (ADPT), iTeos Therapeutics (ITOS), Taysha Gene Therapies (TSHA), and Alector (ALEC). These companies are all part of the "biological products, except diagnostic" industry.

Replimune Group vs.

Replimune Group (NASDAQ:REPL) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, community ranking, earnings, profitability, risk, media sentiment and valuation.

Voyager Therapeutics received 225 more outperform votes than Replimune Group when rated by MarketBeat users. Likewise, 67.44% of users gave Voyager Therapeutics an outperform vote while only 61.54% of users gave Replimune Group an outperform vote.

CompanyUnderperformOutperform
Replimune GroupOutperform Votes
152
61.54%
Underperform Votes
95
38.46%
Voyager TherapeuticsOutperform Votes
377
67.44%
Underperform Votes
182
32.56%

Voyager Therapeutics has a net margin of 52.93% compared to Replimune Group's net margin of 0.00%. Voyager Therapeutics' return on equity of 63.89% beat Replimune Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Replimune GroupN/A -42.94% -35.80%
Voyager Therapeutics 52.93%63.89%40.79%

92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are owned by institutional investors. 20.6% of Replimune Group shares are owned by company insiders. Comparatively, 4.7% of Voyager Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Voyager Therapeutics had 9 more articles in the media than Replimune Group. MarketBeat recorded 10 mentions for Voyager Therapeutics and 1 mentions for Replimune Group. Replimune Group's average media sentiment score of 0.81 beat Voyager Therapeutics' score of 0.24 indicating that Replimune Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Replimune Group
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Voyager Therapeutics
1 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Replimune Group has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500.

Voyager Therapeutics has higher revenue and earnings than Replimune Group. Replimune Group is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Replimune GroupN/AN/A-$174.28M-$3.16-2.04
Voyager Therapeutics$250.01M1.63$132.33M$3.092.43

Replimune Group currently has a consensus price target of $37.67, indicating a potential upside of 483.98%. Voyager Therapeutics has a consensus price target of $19.33, indicating a potential upside of 157.78%. Given Replimune Group's stronger consensus rating and higher probable upside, equities research analysts plainly believe Replimune Group is more favorable than Voyager Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Replimune Group
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Voyager Therapeutics
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86

Summary

Voyager Therapeutics beats Replimune Group on 11 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding REPL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

REPL vs. The Competition

MetricReplimune GroupBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$395.95M$2.58B$4.83B$7.31B
Dividend YieldN/A2.31%2.93%3.99%
P/E Ratio-2.0424.64211.8616.87
Price / SalesN/A266.292,453.9984.33
Price / CashN/A145.7646.5634.42
Price / Book0.663.744.544.15
Net Income-$174.28M-$43.47M$103.98M$214.00M
7 Day Performance-9.66%-9.01%-4.48%-3.52%
1 Month Performance-20.47%-12.62%-6.64%-5.50%
1 Year Performance-61.24%2.74%7.73%3.52%

Replimune Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VYGR
Voyager Therapeutics
3.9911 of 5 stars
$7.98
-3.2%
$19.33
+142.3%
-5.5%$433.31M$250.01M2.58162
TRML
Tourmaline Bio
1.8412 of 5 stars
$17.86
-6.0%
$61.80
+246.0%
N/A$458.11MN/A-1.5744
CCCC
C4 Therapeutics
1.0832 of 5 stars
$6.83
-0.4%
$10.25
+50.1%
+105.5%$468.54M$20.76M-2.56145Gap Down
OCGN
Ocugen
0.869 of 5 stars
$1.59
flat
$4.33
+172.5%
+60.7%$407.84MN/A-4.8284Gap Down
LXEO
Lexeo Therapeutics
1.7305 of 5 stars
$12.23
+1.2%
$20.80
+70.1%
N/A$402.98M$650,000.000.0058News Coverage
EDIT
Editas Medicine
3.6588 of 5 stars
$5.85
-3.8%
$15.00
+156.4%
-28.2%$478.59M$78.12M-2.85265News Coverage
ADPT
Adaptive Biotechnologies
3.845 of 5 stars
$2.75
-5.5%
$6.80
+147.3%
-71.2%$399.00M$170.28M-1.76709Gap Down
ITOS
iTeos Therapeutics
1.2272 of 5 stars
$11.10
-5.6%
$30.33
+173.3%
-22.8%$397.82M$12.60M-3.52157Positive News
TSHA
Taysha Gene Therapies
2.0396 of 5 stars
$2.58
-3.0%
$6.88
+167.0%
+215.3%$481.57M$15.45M-3.8452Analyst Report
ALEC
Alector
3.8227 of 5 stars
$5.31
-5.9%
$14.50
+173.1%
-22.5%$508.43M$97.06M-3.43244

Related Companies and Tools

This page (NASDAQ:REPL) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners